Mustafa Agah TEKİNDAL, Özlem GÜR, Seyran YİĞİT, Demet ETİT, Kemal ATAHAN, Nihan ACAR, Sultan Deniz ALTINDAĞ2, Haldun KAR, Betül KÜÇÜKZEYBEK, Özgün AKGÜL

Clinicopathological features of mammary Paget’s disease: a single-center experience in Turkey

Background/aim: Paget’s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1%–3% of all primary breast tumors. We aimed to evaluate and compare the clinicopathological features and clinical outcome of PD accompanied by in situ carcinoma and invasive cancer. Materials and methods: We used the archive of our pathology laboratory retrospectively for age, sex, history of surgery, histopathological findings, treatment modalities, and follow-up information. We used the Kaplan–Meier method for survival analysis. Results: There were 46 female patients diagnosed with PD. In 39 (84.7%) patients, invasive carcinoma accompanied PD, while 7 (15.3%) patients had ductal carcinoma in situ. The median age at diagnosis was 53.5 years. The median follow-up period was 47 months. Of the 39 invasive carcinoma, 10 (25.6%) died during the follow-up period. Invasive ductal carcinoma group had a mean overall survival of rate of 57.8 ± 6.6 months. According to univariate analysis, only the tumor type was found to impact overall survival (p < 0.001). Conclusions: The current study displayed the tumor type as the only parameter affecting overall survival in the invasive carcinoma group. Although it was not statistically significant, breast cancers accompanied by PD were found to be predominantly advanced stage tumors, high grade, hormone receptor negative, and HER2 positive.Key words: Paget’s disease, breast carcinoma, pathology, molecular subtype, immunohistochemistry

PDF

___

1. Lee HW, Kim TE, Cho SY, Kim SW, Kil WH et al. Invasive Paget disease of the breast: 20 years of experience at a single institution. Human Pathology 2014; 45 (12): 2480-2487. doi: 10.1016/j.humpath.2014.08.015
2. Helme S, Harvey K, AgrawalA. Breast-conserving surgery in patients with Paget’s disease. The British Journal of Surgery 2015; 102 (10): 1167-1174. doi: 10.1002/bjs.9863
3. Wu Q, Ding X, Li J, Sun S, Zhu S et al. Surgical treatment in Paget’s disease with invasive ductal carcinoma: an observational study based on SEER. Scientific Reports 2017; 7: 45510. doi: 10.1038/srep45510
4. Caliskan M, Gatti G, Sosnovskikh I, Rotmensz N, Botteri E et al. Paget’s disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Research and Treatment 2008; 112 (3): 513–521. doi: 10.1007/s10549-007-9880-5
5. Yao Y, Sun L, Meng Y, Zhuang Y, Zhao L et al. Breast-Conserving Surgery in Patients With Mammary Paget’s Disease. The Journal of Surgical Research 2019; 241: 178-187. doi: 10.1016/j. jss.2019.03.025
6. Sisti A, Huayllani MT, Restrepo DJ, Boczar D, Advani P et al. Paget disease of the breast: A national retrospective analysis of the US population. Breast Disease 2020; 39 (3-4): 119-126. doi: 10.3233/BD-200439
7. Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, Yepes MM, Lippman ME. Paget’s disease of the nipple. Breast Cancer Research and Treatment 2013; 141 (1): 1-12. doi: 10.1007/s10549-013-2661-4
8. Zhao Y, Sun HF, Chen MT, Gao SP, Li LD et al. Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population-based study. Cancer Medicine 2018; 7 (6): 2307-2318. doi: 10.1002/cam4.1475
9. Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD et al. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer 2015; 121 (24): 4333-4340. doi: 10.1002/cncr.29687
10. Chen S, Chen H, Yi Y, Jiang X, Lei H et al. Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database. Cancer Medicine 2019; 8 (8): 4043-4054. doi: 10.1002/ cam4.2242
11. Hammond ME, Hayes DF, Dowsett M. American Society of Clinical Oncology; College of American Pathologists, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Archives of Pathology & Laboratory Medicine 2010; 134 (7): 48–72. doi: 10.1043/1543-2165-134.7.e48
12. Wolff AC, Elizabeth M, Hammond H, Hicks DG, Dowsett M et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology 2013; 31 (31): 3997-4014. doi: 10.1200/JCO.2013.50.9984
13. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC et al. International Ki-67 in Breast Cancer Working Group, Assessment of Ki67 in breast 10 cancer: recommendations from the International Ki-67 in Breast Cancer Working Group. Journal of The National Cancer Institute 2011; 103 (22): 1656– 1664. doi: 10.1093/jnci/djr393
14. Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA et al. Breast In: Amin MB, Edge S, Greene F, ByrdDR, BrooklandRK et al (editors) AJCC Cancer Staging Manual. 8th ed. New York, NY, USA: Springer International Publishing; 2016. pp. 589-636.
15. Wong SM, Freedman RA, Stamell E, Sagara Y, Brock JE et al. Modern Trends in the Surgical Management of Paget’s Disease. Annals of Surgical Oncology 2015; 22 (10): 3308-3316. doi: 10.1245/s10434-015-4664-3
16. Zhou H, Lu K, Zheng L, Guo L, Gao Y et al. Prognostic significance of mammary Paget’s disease in Chinese women: a 10-year, population-based, matched cohort study. OncoTargets and Therapy 2018; 11: 8319-8326. doi: 10.2147/OTT.S171710
17. Ortiz-Pagan S, Cunto-Amesty G, Narayan S, Crawford S, Derrick C et al. Effect of Paget’s Disease on Survival in Breast Cancer. Archives of Surgery 2011; 146 (11): 1267-1270. doi: 10.1001/archsurg.2011.278
18. Kim YJ, Lee KH, Lee WJ, Won CH, Chang SE et al. Clinicopathological characteristics of mammary Paget’s disease: A single-center 25-year experience in Korea. The Breast Journal 2020; 26 (4): 806-808. doi: 10.1111/tbj.13651
19. Challa VR, Deshmane V. Challenges in Diagnosis and Management of Paget’s Diease of the Breast- a Retrospective Study. The Indian Journal of Surgery 2015; 77 (Suppl 3): 1083- 1087. doi: 10.1007/s12262-014-1167-6
20. Durkan B, Bresee C, Bose S, Phillips EH, Dang CM. Paget’s disease of the nipple with parenchymal ductal carcinoma in situ is associated with worse prognosis than Paget’s disease alone. The American Surgeon 2013; 79 (10): 1009-1012. doi: 10.1177/000313481307901011
21. Wachter DL, Wachter PW, Fasching PA, Beckmann MW, Hack CC et al. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. Archives of Pathology & Laboratory Medicine 2019; 143 (2): 206-211. doi: 10.5858/arpa.2017-0578- OA
22. Dalberg K, Hellborg H, Wärnberg F. Paget’s disease of the nipple in a population based cohort. Breast Cancer Research and Treatment 2008; 111 (2): 313-319. doi: 10.1007/s10549- 007-9783-5
23. Bouzaiene H, Mezghani B, Slimane M, Goucha A, Ariane A, Naija L et al. Paget’s Disease of the Female Breast: Clinical Findings and Management in 53 Cases at a Single Institution. Middle East Journal of Cancer 2016; 7 (3): 145-149.
24. Arafah M, Arain SA, Raddaoui EMS, Tulba A, Alkhawaja FH et al. Molecular subtyping of mammary Paget’s disease using immunohistochemistry. Saudi Medical Journal 2019; 40 (5): 440-446. doi: 10.15537/smj.2019.5.23967
25. Sek P, Zawrocki A, Biernat W, Piekarski JH. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study. Histopathology 2010; 57 (4): 564-571. doi: 10.1111/j.1365-2559.2010.03665.x
26. Lester T, Wang J, Bourne P, Yang Q, Fu L et al. Different panels of markers should be used to predict mammary Paget’s disease associated with in situ or invasive ductal carcinoma of the breast. Annals of Clinical and Laboratory Science 2009; 39 (1): 17-24.